4F-MPH: Difference between revisions

>N00nehere
added legality status for italy
>Blackhole
added important category
(One intermediate revision by one other user not shown)
Line 18: Line 18:
==Pharmacology==
==Pharmacology==
{{Stub}}
{{Stub}}
4F-MPH is thought to act primarily as a [[dopamine and norepinephrine]] [[reuptake inhibitor]], meaning it effectively boosts the levels of dopamine and norepinephrine [[neurotransmitters]] in the brain by binding to and partially blocking the transporter proteins that normally clear these catecholamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the reward pathways in the brain, resulting in stimulating and euphoric effects.  
4F-MPH is thought to act primarily as a [[dopamine]] and [[norepinephrine]] [[reuptake inhibitor]], meaning it effectively boosts the levels of dopamine and norepinephrine [[neurotransmitters]] in the brain by binding to and partially blocking the transporter proteins that normally clear these catecholamines from the synaptic cleft. This allows dopamine and norepinephrine to accumulate within the reward pathways in the brain, resulting in stimulating and euphoric effects.  


According to a pharmacological evaluation, the ''(±)-threo'' isomer of 4F-MPH is 2.15 times more effective at dopamine reuptake inhibition, and 2.7 times more at norepinephrine reuptake inhibition, than its parent compound methylphenidate. The ''(±)-erythro'' isomer, however, is 65 times less effective at dopamine reuptake inhibition and 45.6 times less effective at norepinephrine reuptake inhibition than methylphenidate. Neither racemate of 4F-MPH has a significant impact on serotonin reuptake.<ref>{{cite journal | vauthors=((McLaughlin, G.)), ((Morris, N.)), ((Kavanagh, P. V.)), ((Power, J. D.)), ((Dowling, G.)), ((Twamley, B.)), ((O’Brien, J.)), ((Hessman, G.)), ((Murphy, B.)), ((Walther, D.)), ((Partilla, J. S.)), ((Baumann, M. H.)), ((Brandt, S. D.)) | journal=Drug Testing and Analysis | title=Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)- threo and (±)- erythro diastereomers: Analytical characterization and pharmacological evaluation of 4-fluoromethylphenidate | volume=9 | issue=3 | pages=347–357 | date= March 2017 | url=https://onlinelibrary.wiley.com/doi/10.1002/dta.2167 | issn=19427603 | doi=10.1002/dta.2167}}</ref>
According to a pharmacological evaluation, the ''(±)-threo'' isomer of 4F-MPH is 2.15 times more effective at dopamine reuptake inhibition, and 2.7 times more at norepinephrine reuptake inhibition, than its parent compound methylphenidate. The ''(±)-erythro'' isomer, however, is 65 times less effective at dopamine reuptake inhibition and 45.6 times less effective at norepinephrine reuptake inhibition than methylphenidate. Neither racemate of 4F-MPH has a significant impact on serotonin reuptake.<ref>{{cite journal | vauthors=((McLaughlin, G.)), ((Morris, N.)), ((Kavanagh, P. V.)), ((Power, J. D.)), ((Dowling, G.)), ((Twamley, B.)), ((O’Brien, J.)), ((Hessman, G.)), ((Murphy, B.)), ((Walther, D.)), ((Partilla, J. S.)), ((Baumann, M. H.)), ((Brandt, S. D.)) | journal=Drug Testing and Analysis | title=Analytical characterization and pharmacological evaluation of the new psychoactive substance 4-fluoromethylphenidate (4F-MPH) and differentiation between the (±)- threo and (±)- erythro diastereomers: Analytical characterization and pharmacological evaluation of 4-fluoromethylphenidate | volume=9 | issue=3 | pages=347–357 | date= March 2017 | url=https://onlinelibrary.wiley.com/doi/10.1002/dta.2167 | issn=19427603 | doi=10.1002/dta.2167}}</ref>
Line 129: Line 129:
<references />
<references />


[[Category:Psychoactive substance]]
[[Category:Phenidate]]
[[Category:Phenidate]]
[[Category:Research chemical]]
[[Category:Research chemical]]
[[Category:Stimulant]]
[[Category:Stimulant]]
Retrieved from "http://psy.st/wiki/4F-MPH"